0001209191-13-053649.txt : 20131121 0001209191-13-053649.hdr.sgml : 20131121 20131121200230 ACCESSION NUMBER: 0001209191-13-053649 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131119 FILED AS OF DATE: 20131121 DATE AS OF CHANGE: 20131121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001347178 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030491827 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 BUSINESS PHONE: 202-734-3400 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Repella Robert CENTRAL INDEX KEY: 0001532513 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34186 FILM NUMBER: 131236588 MAIL ADDRESS: STREET 1: 1410 PARSONS LANE CITY: AMBLER STATE: PA ZIP: 19002 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-11-19 0 0001347178 Vanda Pharmaceuticals Inc. VNDA 0001532513 Repella Robert 2200 PENNSYLVANIA AVENUE SUITE 300E WASHINGTON DC 20037 0 1 0 0 SVP & Chief Commercial Officer Common Stock 2013-11-19 4 S 0 2885 12.0724 D 21490 D Common Stock 2013-11-20 4 M 0 40515 5.90 A 62005 D Common Stock 2013-11-20 4 S 0 40515 11.8884 D 21490 D Common Stock 2013-11-21 4 M 0 23040 5.90 A 44530 D Common Stock 2013-11-21 4 M 0 34570 3.12 A 79100 D Common Stock 2013-11-21 4 S 0 64100 12.1184 D 15000 D Employee Stock Option (Right to Buy) 5.90 2013-11-20 4 M 0 40515 0.00 D 2021-10-24 Common Stock 40515 189485 D Employee Stock Option (Right to Buy) 5.90 2013-11-21 4 M 0 23040 0.00 D 2021-10-24 Common Stock 23040 166445 D Employee Stock Option (Right to Buy) 3.12 2013-11-21 4 M 0 34570 0.00 D 2022-12-06 Common Stock 34570 21680 D Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of certain Restricted Stock Units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.115, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.46, inclusive. The option becomes exercisable with respect to 25% of the shares after 12 months of continuous service with the Issuer, with the balance becoming exercisable in equal monthly installments over the next 36 months of continuous service thereafter. 50% of the shares subject to this option shall vest in 48 equal monthly installments beginning January 7, 2013 (the "Initial Vesting Date"), provided Reporting Person remains continuously employed by the Issuer through the Initial Vesting Date. 50% of the shares subject to this option shall vest upon acceptance by the U.S. Food and Drug Administration of the Issuer's New Drug Application Filing for tasimelteon for the treatment of Non-24-Hour Disorder (the "Vesting Event"), provided Reporting Person remains continuously employed by the Issuer through the Vesting Event. /s/ Robert Repella 2013-11-21